In today’s world, there may be one thing may be perceived as a higher value than money, and that is convenience. Over the past decade, we have seen a significant shift in consumer behavior, mainly due to technological advances, towards an on-demand consumer model. This shift emerged with the start of e-commerce, beginning with the ability to order goods online to be delivered and it has now evolved to an era where one can order nearly anything without even getting out of bed.
Companies like Amazon (AMZN) and Netflix (NFLX) were at the forefront of this shift and their success could be largely due to seeing the value in providing consumers with convivence early on.
But now, this on-demand industry is rapidly replacing traditional business models by providing consumers what they want, where they want and when they want. The newest part of this model that has emerged is food delivery, and it may just satisfy an investors appetite.
Who’s Focusing On Delivering Profit For Investors?
ParcelPal Technology Inc. (PTNYF) (PKG) is a Canadian technology-driven logistics company purposed with connecting consumers to the goods they love through partner businesses, from food to clothes to even cannabis, all within an hour. The company recently achieved a major milestone of completing over 2 million deliveries and announced its plans for further expansion throughout Canada and into the U.S.
Notably, ParcelPal has secured a work order contract with Amazon to fulfill package delivery on behalf of Amazon in 3 western Canadian markets and Evert, Washington. The company has also entered key verticals with businesses in both alcohol and cannabis. ParcelPal has inked two delivery agreements with two Canadian cannabis companies, in which one cannabis delivery initiative went live mid-April.
ParcelPal will be hosting an investor update conference call on May 1st to review recent progress and that will be releasing its quarterly financial statements for Q4 FY2018 by April 30, 2019.
GrubHub (GRUB) is a leading online and mobile food-ordering and delivery marketplace that works with over 105,000 restaurant partners throughout the US. and London. The company recently annouced its financial results for Q1 2019 which followed the momentum seen in 2018. GrubHub reported revenues of $324 million, a 39% year-over-year increase Q1 2018’s $233 million, while gross food sales grew 21% to $1.5 billion year-over-year, up from $1.2 billion the year prior.
“We are extremely proud of our entire team for another fantastic quarter of execution – record new diner growth, thousands of new quality restaurants added to our platform and a sixth consecutive quarter of organic order acceleration.
Even with our recent ramp in growth investments, adjusted EBITDA per order improved during the quarter, underscoring our ability to grow in a long-term sustainable manner,” said Grubhub Founder and CEO Matt Maloney.
Yum! Brands Inc. (YUM) is the parent company of well-known restaurant chains such as KFC, Pizza Hut, and Taco Bell. The company entered the delivery space in late 2017 following its U.S. partnership with Grubhub for pickup and delivery service. In this deal, Yum Brands also purchased $200 million of Grubhub’s common stock, giving it a not only a large vested interest in the company but also a seat on GrubHub’s board of directors.
“We are committed to making our iconic brands easier to access through online ordering for pickup and delivery, and aggressively pursuing delivery as a strategic global growth opportunity, with nearly half of our 45,000 restaurants already offering it today,” said Greg Creed, CEO, Yum! Brands, Inc at the time of the press release.
“We’re pleased to secure this partnership with Grubhub in order to drive incremental, profitable growth for our U.S. franchisees over the long term. Our partnership and strategic investment in Grubhub demonstrate our laser-like focus on two of our growth drivers: Distinctive, Relevant & Easy Brands and Unmatched Franchise Operating Capability.”
And The Usual Suspects?
Domino’s Pizza (DPZ) is the largest pizza company in the world based on retail sales, with a significant business in both delivery and carryout pizza. Through the company’s platform, Domino’s Anywhere, consumers have the convenience to order pizza through options such as Google Home, Amazon’s Alexa and Facebook Messenger.
Last year, Dominos launched its Hotspot program that gave consumers access to have their orders delivered to hundreds of thousands of public areas as well and when the company reported earnings for that quarter revenues increased 25.8% to $161.2 million.
Most recently, a piloting a test of GPS driver tracking began in 27 corporate-owned stores throughout Phoenix, Arizona expected to extend into later markets this spring. This new initiative allows consumers to track their order and driver and receive an estimated delivery time as well as text notifications.
McDonald’s (MCD) is the world’s leading global foodservice retailer with around 38,000 locations in over 100 countries. Although McDonald’s technically doesn’t deliver, the fast food company teamed up with UberEats in the U.S. 2017, after trials in the Middle East and Asia, and now offers delivery through this exclusive partnership in over 8,000 locations worldwide.
McDonald’s reported Q1 2019 earnings of $1.78 per share in the on revenue of $4.956 billion versus expectations of $1.77 per share and $4.93 billion. Global comparable sales were 5.4 percent higher in the quarter, including a 4.5 percent increase in the U.S. market.
The burger giant’s efforts to expand its delivery network with Uber Eats has been slower in the U.S than other markets, however that delivery checks were 1.5 to 2 times the size of an in-store check and that delivery was a $3 billion business globally for the company.
MIDAM VENTURES LLC has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG). Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to May 1, 2019. We may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. Click Here For Full Disclaimer
3 Penny Stocks Looking To Change The Biotech Industry
The world of biotech investing can be tricky. That’s particularly true when it comes to small-cap stocks in the industry. These companies often have terrific science, but no profits and little revenue; if any at all. But biotech stocks can offer true potential for investors who know what to look for.
Perhaps the best strategy for gaining exposure to this space is to look at early-stage, small-cap biotechs. By doing so, you put yourself at the front-line for cutting edge, experimental companies that could one day hit it big. Given this, here are 3 small-cap biotechs working to evolve in the biotech industry.
GT Biopharma Inc. (GTBP)
One company making groundbreaking developments in the biotechnology field is GT Biopharma Inc. (GTBP). GT Biopharma Inc. is an immune-oncology biotech company determined to create new treatments for cancer. In order to do this, the company leverages its proprietary TriKE technology to develop its pipeline. As of now, GT Biopharma has 6 treatment plans undergoing the clinical trial process.
So, what exactly is this TriKE technology platform? TriKE is actually an acronym for tri-specific killer engagers that are made to target NK’s or natural killer and tumor cells. Once they target NK cells, it binds to the CD16 receptor which makes a longer and stronger response compared to current treatment methods.
One use of TriKE has been to develop a way to target the HIV-Env protein. The design to do this is known as HIV-TriKE. As a matter of fact, the company recently announced data that showed the effectiveness of HIV-TriKE. It was shown that it enhanced NK cell cytokine production and effectively killed infected targets with HIV-Env.
“We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease and is able to kill HIV in the reservoir.” Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy,” expressed Anthony Cataldo, CEO and Chairman of GE Biopharma.
Conatus Pharmaceuticals Inc. (CNAT)
This next biotechnology company is known as Conatus Pharmaceuticals Inc. (CNAT). This company’s focus is different compared to GT Biopharma. It aims to treat chronic diseases that have a large unmet need. Its lead product candidate CTS-2090, inhibits IL-1β which treats inflammatory diseases.
In terms of news releases, the company has been slightly lackluster over the last two months. However, in early August Conatus released its Q2 financials which showed some profitability promise in its income statement.
Revenues increased and expenses decreased in Q2 2019 compared to Q2 2018 which significantly reduced the company’s net loss by $3.8 million. One potential hindrance factor in the financials could be Conatus’ consistently declining free cash flow.
Nuvectra Corporation (NVTR)
To top things off, we have a neurostimulation company known as Nuvectra Corporation (NVTR). The company has a commercial product called Algovita Spinal Cord Stimulation which treats chronic pain of the trunk and limbs. In addition to this, Nuvectra is awaiting FDA pre-market approval for its Virtis Sacral Neuromodulation which treats chronic urinary retention and overstive bladders.
Compared to Conatus, Nuvectra has produced recent news that investors can sink their teeth into. First off, the company appointed Jennifer Kosharek as CFO around a month ago. This is a strong appointment thanks to her 15+ years of accounting experience and other leadership positions with Nuvectra.
Furthermore, the company recently submitted its supplementary chemical composition and biocompatibility data to the FDA to support Virtis’ pre-market approval.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma Inc. (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma Inc. (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma Inc. (GTBP). Full Disclaimer Click Here
Are These Biotech Names On Your October Watch List?
Over the past two decades, the biotech sector has been one of the best sectors to watch. If experts are to be believed, then it is likely to continue to be a hot sector for the foreseeable future. However, biotech stocks require research and that can help when it comes to making a list of biotech stocks.
Once that is done, the investor needs to track the companies closely. Then it’s easier to decide upon the best course of action. Here is a look at three biotechnology penny stocks this month.
Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)
If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.
David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.
“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”
Over the last week, shares of PMCB stock have jumped from $0.0319 to highs of $0.0367 on Friday.
Biotech Stocks To Watch: Hepion Pharmaceuticals (HEPA)
The next biotech stock to watch is Hepion Pharmaceuticals Inc (NASDAQ:HEPA). The company is involved in manufacturing medicines meant for liver conditions emanating from non-alcoholic reasons. The company announced that its research article has been published by the highly influential peer-reviewed journal, the Journal of Pharmacology and Experimental Therapeutics.
The paper in question is titled “A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.” The study shows that Hepion’s product CRV431 could well be a solution for treating chronic diseases of the liver. The paper also stated that the medicine is suited to address a range of therapeutic needs.
Once the news broke, the company’s stock started soaring and soared over 43% at $3.58, well off the session high of $5.59.
Biotech Stocks To Watch: Protalix Biotherapeutics (PLX)
The other biotech stock that broke out more this week is Protalix Biotherapeutics Inc (NYSE:PLX). The company released data from the BRIDGE Phase 3 clinical study of its product PRX-102 and the revelations have proven to be highly encouraging. Out of a total of 22 patients who had been enrolled for the study, the data was gleaned from 16 of them.
The patients in question had been treated with PRX-102 for 12 months. The medicine is meant for treating Fabry disease and it has been revealed that there was an improvement in the function of kidneys in the patients. The stock soared by as much as 75% on Thursday and should definitely be on the watch lists of most investors.
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here.
Stock Price Newsletter – October 18, 2019
Biotech ETF’s Just Hit New Highs: 3 Stocks To Watch
The biotech sector has a plethora of stocks though. Therefore, an investor needs to put in the necessary research. On that note, here is a look at three biotech stocks to watch as sector stocks enjoy a bull run in October.
In Case You Missed It: Sernova (SVA) (SEOVF) Finds C-Peptide In Phase I/II Fasting Patient
Sernova Corp. (SVA) (SEOVF) has detected enduring levels of C-peptide (measured up to 30 days and continuing), a biomarker of transplanted beta cell insulin production, in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes.
These Healthcare & Biotech Stocks Deserve Your Attention This Month
The positive results provided a break for the sector. Furthermore, healthcare stocks have risen by 5.7% this year. The entire index has seen a nearly 20 percent gain, according to The Wall Street Journal. With this in mind, healthcare and biotechnology stocks are in focus this month.
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Featured4 days ago
What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!
Biotechnology1 week ago
Biotech Stocks In Focus Amid New Wave Of Drug Delivery
Biotechnology2 weeks ago
Top Biotechnology Stocks To Watch This Quarter
Biotechnology1 week ago
3 Top Biotech Stocks To Monitor In October
Biotechnology3 days ago
Healthcare Stocks To Watch Amid Bullish Earnings
Biotechnology2 weeks ago
Top Biotechnology Stocks To Watch After Latest News
Biotechnology2 days ago
Biotech Stocks To As Sector ETF’s Climb Higher
Biotechnology1 week ago
Biotechnology Stocks Gaining Ground In October; What To Watch